So far, six immune checkpoint inhibitors targeting PD-1/PD-L1 have been approved by the FDA for the first and second line of patients with non-small cell lung cancer including monoclonal antibodies (mAb) pembrolizumab, nivolumab and cemiplimab targeting PD-1 and mAb atezolizumab, avelumab and durvalumab targeting PD-L1. This evidence concerns the gene CD274 and non-small cell lung carcinoma.